39 completed, 7 recruiting, 4 not yet recruiting, 3 active not recruiting. 25 Phase 3, 16 Phase 2, 8 Phase 1, 5 Phase 4.
Follow bimekizumab: new trials by email Literature Review of bimekizumab trials Research Report on bimekizumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluation of the Efficacy and Safety of Bimekizumab (BZK) or Adalimumab (ADA) in the Treatment of Anterior Chest Wall Pain Associated With Active Axial Spondyloarthritis Refractory to NSAIDs With Hypothesis of Superiority of Bimekizumab bimekizumab, adalimumab - Axial or Predominantly Axial SpondyloArthritis With or Without Psoriasis | Phase 3 | Not yet recruiting | University Hospital, Rouen | 150 | 2026-10-15 | 2026-09-23 |
| Bimzelx (Bimekizumab) For The Treatment Of Adult Onset Pityriasis Rubra Pilaris (PRP) Bimekizumab - Pityriasis Rubra Pilaris | Phase 4 | Not yet recruiting | Mayo Clinic | 12 | 2026-10-01 | 2026-09-08 |
| A Study of SPY072 in Adults With Moderate to Severe Hidradenitis Suppurativa (The SKYLIGHT Trial) SPY072, Placebo, bimekizumab - Hidradenitis Suppurativa (HS) | Phase 2 | Recruiting | Spyre Therapeutics, Inc. | 150 | 2026-09-01 | 2026-10-19 |
| Efficacy of Bimekizumab in Adults With Pyoderma Gangrenosum Bimekizumab - Pyoderma Gangrenosum | Phase 2 | Not yet recruiting | Oregon Health and Science University | 15 | 2026-09-01 | 2026-08-17 |
| Utilization of a Microdevice for Psoriasis and Atopic Dermatitis In situ cutaneous microdevice, Triamcinolone, 5-Fluorouracil - Psoriasis, Atopic Dermatitis | Phase 4 | Not yet recruiting | University of California, San Francisco | 10 | 2026-08-01 | 2026-06-03 |
| Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty Methotrexate, Sulfasalazine, Hydroxychloroquine - Rheumatic Disease | Phase 2 | Recruiting | NYU Langone Health | 80 | 2025-12-12 | 2026-07-09 |
| A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Palmoplantar Pustulosis Bimekizumab, Placebo - Palmoplantar Pustulosis | Phase 3 | Recruiting | UCB Biopharma SRL | 320 | 2025-11-14 | 2026-08-27 |
| A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab) Bimekizumab - Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis | Phase 1 | Recruiting | UCB Biopharma SRL | 20 | 2025-11-05 | 2026-09-18 |
| Early Intervention in Plaque Psoriasis: is Bimekizumab Able to Delay Chronic Inflammation? Bimekizumab, Clobetasol - Psoriasis | Phase 2 | Recruiting | Centre Hospitalier Universitaire de Nice | 40 | 2025-07-22 | 2026-10-01 |
| Evaluating the Role of IL-17 as an Orchestrator of Peripheral-central Cross Talk in Depressive Symptoms Secukinumab, Bimekizumab, Ixekizumab - Psoriatic Arthritis, Depression | Recruiting | NHS Greater Glasgow and Clyde | 50 | 2025-06-02 | 2025-06-19 | |
| A Study to Assess the Pharmacokinetics and Safety of Bimekizumab in Children and Adolescents With Moderate to Severe Hidradenitis Suppurativa Bimekizumab - Hidradenitis Suppurativa | Phase 3 | Active not recruiting | UCB Biopharma SRL | 43 | 2025-04-07 | 2026-09-25 |
| An Open-label Study to Evaluate the Pharmacokinetics and Safety of Bimekizumab in Pediatric Study Participants With Active Juvenile Idiopathic Arthritis Subtypes Enthesitis-related Arthritis (Including Juvenile-onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis Bimekizumab - Enthesitis-related Arthritis, Juvenile Psoriatic Arthritis | Phase 3 | Recruiting | UCB Biopharma SRL | 40 | 2025-03-11 | 2026-10-23 |
| A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants With Active Psoriatic Arthritis Bimekizumab, Risankizumab, Placebo - Psoriatic Arthritis | Phase 3 | Completed | UCB Biopharma SRL | 553 | 2024-10-21 | 2026-09-02 |
| A Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants With Moderate to Severe Plaque Psoriasis bimekizumab - Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis | Phase 3 | Active not recruiting | UCB Biopharma SRL | 89 | 2024-07-29 | 2026-07-17 |
| A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Ustekinumab in Children and Adolescents From 6 Years to Less Than 18 Years of Age With Moderate to Severe Plaque Psoriasis bimekizumab, ustekinumab, placebo - Moderate to Severe Plaque Psoriasis | Phase 3 | Active not recruiting | UCB Biopharma SRL | 176 | 2024-06-25 | 2026-09-18 |
| Bimekizumab in Plaque Psoriasis Bimekizumab - Plaque Psoriasis | Phase 4 | Completed | Icahn School of Medicine at Mount Sinai | 60 | 2024-06-03 | 2026-04-20 |
| A Study to Evaluate the Efficacy and Safety of Bimekizumab in Chinese Adult Study Participants With Moderate to Severe Plaque Psoriasis Placebo, Bimekizumab - Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis | Phase 3 | Completed | UCB Biopharma SRL | 133 | 2023-10-31 | 2026-06-26 |
| Effect of Bimekizumab in Patients With Psoriasis Vulgaris and Active Psoriatic Arthritis Bimekizumab - Psoriasis Vulgaris, Active Psoriatic Arthritis | Phase 4 | Withdrawn | Innovaderm Research Inc. | 2023-01-01 | 2023-03-15 | |
| A Bioequivalence Study of Bimekizumab Given as 1x2mL or 2x1mL Subcutaneous Injection Using an Autoinjector in Healthy Study Participants bimekizumab - Healthy Study Participants | Phase 1 | Completed | UCB Biopharma SRL | 121 | 2022-03-17 | 2025-04-10 |
| A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Korean Study Participants With Moderate to Severe Plaque Psoriasis bimekizumab, Placebo - Moderate to Severe Plaque Psoriasis | Phase 3 | Completed | UCB Biopharma SRL | 47 | 2021-09-27 | 2025-03-18 |
Showing 20 of 55. Sign in to see all of them.
Psoriasis (18) · Arthritis, Psoriatic (15) · Hidradenitis Suppurativa (7) · Spondylitis, Ankylosing (6) · Axial Spondyloarthritis (4) · Arthritis (2) · Arthritis, Juvenile (2) · Arthritis, Rheumatoid (2) · Non-Radiographic Axial Spondyloarthritis (2) · Skin Diseases (2) · Aggressive Periodontitis (1) · Depression (1) · Dermatitis, Atopic (1) · Dermatomyositis (1) · Giant Cell Arteritis (1)
UCB Biopharma SRL (35) · UCB Biopharma S.P.R.L. (5) · UCB Celltech (4) · Centre Hospitalier Universitaire de Nice (1) · Icahn School of Medicine at Mount Sinai (1) · Innovaderm Research Inc. (1) · Mayo Clinic (1) · NHS Greater Glasgow and Clyde (1) · NYU Langone Health (1) · Oregon Health and Science University (1) · Radboud University Medical Center (1) · Spyre Therapeutics, Inc. (1) · University Hospital, Rouen (1) · University of California, San Francisco (1)
United States (42) · Germany (32) · Poland (29) · Canada (25) · Hungary (23) · Czechia (20) · United Kingdom (20) · Spain (16) · Australia (15) · Russia (15) · Japan (14) · Belgium (13) · France (13) · Bulgaria (9) · Italy (9)
Elke de Jong, MD, PhD (1) · Jason C. Sluzevich, MD (1) · Jonathan Cavanagh, MD, PhD (1) · Jonathan Samuels, MD (1) · Joshua Friedman, MD, PhD (1) · Mark Lebwohl, MD (1) · Raymond Cho, MD, PhD (1) · Robert Bissonnette, MD (1) · Thierry Passeron, PhD (1)
PMID 40194794, PMID 41807031, PMID 35544084, PMID 42386286, PMID 39578348, PMID 41060492, PMID 41580158, PMID 41800601, PMID 36751950, PMID 37950894, PMID 40286813, PMID 40886218, PMID 41359217, PMID 38446397, PMID 38488975, PMID 38754125, PMID 39120849, PMID 39215949, PMID 39534481, PMID 40347389, PMID 41125403, PMID 41248770, PMID 41314667, PMID 41381988, PMID 41838419, PMID 42128532, PMID 42152504, PMID 42297437, PMID 42482599, PMID 42525209, PMID 42860055, PMID 34260044, PMID 35789257, PMID 35833532, PMID 36649967, PMID 36689515, PMID 37793792, PMID 38073049, PMID 38588819, PMID 38599650, PMID 38795716, PMID 38834351, PMID 38977276, PMID 39120848, PMID 39133438, PMID 39313302, PMID 39406403, PMID 39890205, PMID 39892885, PMID 40153232
2016 (10), 2017 (10), 2023 (7), 2019 (5), 2018 (2), 2014 (1), 2025 (1)